HTB

2018

Featured 12 December 2018: vol 19 no 18: Final issue of 2018

Glasgow HIV Congress (2018) – second reports

Hepatitis C is an independent risk factor for preterm delivery in HIV positive women: data from a Warsaw cohort

Vertical transmission remains very low in UK and Ireland: update from the National Study of HIV in Pregnancy and Childhood 

3rd HIV Research for Prevention Conference (R4P2018) – second reports

3D printing technology has potential to individualise production of vaginal rings

22nd International AIDS Conference (AIDS 2018) – final report

No significant decrease in raltegravir free fraction during pregnancy

Updates from Liverpool University drug interactions website

FDA approves generic TDF/3TC for use in the US

New community recommendations for HIV cure studies that include a treatment interruption

IAS condemns Tanzania’s anti-gay initiatives

Essential viewing: Live Growing Up – CHIVA 2018 video…

12 December 2018: vol 19 no 18

Doravirine (Pifeltro) and doravirine/TDF/3TC FDC (Delstrigo) approved in Europe

Featured 13 November 2018: vol 19 no 17: HIVR4P and Glasgow conferences: first reports

Glasgow HIV Congress (2018)

No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts

Insufficient data on risk of neural tube defects with exposure to elvitegravir or bictegravir exposure during preconception or first trimester

Viral dynamics of dolutegravir-based dual versus triple ART

Ibalizumab: 48-week phase 3 results in 27 participants with MDR HIV

Fostemsavir: 48-week phase 3 results from BRIGHTE study

Dolutegravir non-inferior to low dose efavirenz in real-life African study conducted in Cameroon  

3rd HIV Research for Prevention Conference (R4P2018)

How to evaluate PrEP and vaccines: urgency for next generation compounds

Dual bNAb maintains viral suppression for median 21 weeks off-ART

Cabotegravir levels can be detected several years: PK tail to be covered by oral PrEP

3D imaging show HIV infection might establish within hours

bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges

Why U=U does not cover breastfeeding

FDA updates rilpivirine label for use during pregnancy

EACS guidelines – version 9.1 update (2018)

Activists demand $1 a day access to bedaquiline for MDR TB

Cannabis-based products for medicinal use: Guidance to clinicians

13 November 2018: vol 19 no 17

Featured 19 October 2018: vol 19 no 16: BHIVA and Ageing Conferences, PrEP guidelines

BHIVA Autumn Conference 2018

Second case of potential HIV eradication

New UK PrEP guidelines 2018

Other selected talks at BHIVA Autumn 2018

9th International Workshop on HIV and Ageing

Detectable viral load quadruples odds of recurrent falls in older men with HIV

Dolutegravir/lamividune FDC submitted to EMA and FDA

More than 40% of HIV group has hepatic steatosis, regardless of age

Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV – 18% lonely quite often

Physical function worse in older women than men with HIV, despite better CD4 recovery

Post-AIDS 2018 updates on HIV cure research

UK government funding cuts leave sexual health and HIV care at breaking point

Brazilian court suspends patent on hepatitis C medicine sofosbuvir

UK PrEP guidelines now online (2018)

HIV positive mother is living donor to negative child: HIV is considered an acceptable outcome of liver transplant

LGBT HIV activist Zak Kostopoulos murdered in Athens: campaign calls for justice

19 October 2018: vol 19 no 16

19 September 2018: vol 19 no 15

Featured 19 September 2018: vol 19 no 15: UK diagnoses, U=U resources, generic PrEP

U=U resources for UK clinics: free posters, postcards and factsheets

HIV diagnoses in UK drop for third year: among all ages, risk groups, and ethnicities and across most UK regions

22nd International AIDS Conference (AIDS 2018) – third reports

Dolutegravir twice daily is effective and tolerable with rifampicin: 48 week results from the INSPIRING study

TAF exposures during pregnancy and postpartum appear adequate but more data are needed

High rate of unintended pregnancy among HIV positive African women on ART

English court finds in favour of access to generic TDF/FTC

FDA approves doravirine (Pifeltro) and new FDC with TDF/3TC (Delstrigo) in the US

FDA update labels for dolutegravir and dolutegravir-based FDCs to reflect potential risk of neural tube defects

Alcohol and HIV: new issue of RITA

Post navigation